Replimune (REPL) Net earnings per share growth forecast for next year

Symbol and logo of brand Replimune Corp (REPL)

Replimune Group, Inc. (REPL) management strictly adheres to biohazardous waste disposal protocols. The change in the consensus earnings per share forecast on the GURU.Markets chart demonstrates the results of this work, where 41.20 becomes the new value for the indicator. Development is complicated by stringent FDA regulations and patent barriers, as well as a high probability of clinical phase failures in the oncolytic virus scientific race.

REPL - Replimune Corp Earnings growth forecast for next year over the range 07/04/2022 - 11/12/2026

Metric breakdowns and analytics for replimune.com (REPL)

- price and consensus price forecast:
Price Chart Replimune Corp|REPL - Consensus Target
- market capitalization details:
Market Value Replimune|REPL - Real Price to Acquire Entire Company
- company book value details:
Accounting Value per Share Replimune|REPL - Book Capitalization|Market Value to Book Value Ratio replimune.com|REPL - Total Business Assets
- company liabilities and liquidity data:
Debt to Equity Replimune Group, Inc.|REPL - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Replimune|REPL - Company Total Indebtedness|Debt to Book Value Replimune|REPL - Amount of Long-Term Liabilities|Company Short-Term Debts Replimune|Quick Ratio replimune.com
- earnings and market ratios statistics:
REPL - Company Net Income|Expected Profit Replimune Group, Inc.|REPL - Company Value to Net Income|Forward P/E Multiple Replimune Group, Inc.|REPL - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Replimune|REPL - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share for the last 12 months Replimune|REPL - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months replimune.com|REPL - Earnings per share increase in current year|Earnings growth forecast for next year Replimune Group, Inc.
Analysis of all company metrics:Replimune Corp
Core merchandise of Replimune Group Inc

For Replimune Group, Inc. (REPL), a developer of oncolytic viruses, this indicator serves as a measure of investment attractiveness amid fierce biotech competition. The metric is calculated as the percentage change in expected earnings per share for the following year relative to current values. By analyzing the trend of the forward net income figure, investors assess the probability of commercial success for patented developments. Rising values signal market confidence in the efficacy of drug combinations with checkpoint inhibitors.

Direct competitors

Net earnings per share growth forecast for next year ImmunityBio Corp|Expected earnings per share growth for next year Immunocore Corp (IMCR)|Net earnings per share growth forecast for next year Janux Therapeutics (JANX)|Expected earnings per share growth for next year arcusbio.com RCUS|Zymeworks - Expected earnings per share growth for next year|Earnings growth forecast for next year Tango Therapeutics Inc TNGX|IOVA - Net earnings per share growth forecast for next year|IMTX (Immatics Biotechnologies) - Projected earnings per share growth rate for next year|Xencor, Inc. (XNCR) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year compasstherapeutics.com (CMPX)|Expected earnings per share growth for next year LYEL|IPHA - Net earnings per one share growth forecast for next year|Expected earnings per share growth for next year PYXS (Pyxis Oncology, Inc.)|Projected earnings per share increase next year CGEN|Earnings growth forecast for next year IOBT (IO Biotech, Inc.)|Expected earnings per share trend next year STRO|MiNK Therapeutics - Earnings growth forecast for next year|Expected net earnings per share growth next year Werewolf Therapeutics|immixbio.com (IMMX) - Net earnings per share growth forecast for next year|ALX Oncology Holdings Inc. - Expected earnings per share trend next year|CUE (Cue Biopharma, Inc.) - Earnings growth forecast for next year|Earnings growth forecast for next year PDS Biotechnology Corp|Net earnings per share growth forecast for next year Sonnet BioTherapeutics (SONN)|MAIA: Net earnings per share change forecast for next year|Liminatus Pharma Corp - Expected earnings per share growth for next year|LAVA Therapeutics NV (LVTX) - Expected net earnings per share growth next year|NXTC - Net earnings per share growth forecast for next year|Expected earnings per share trend next year LPTX (Leap Therapeutics, Inc.)|INTS: Earnings growth forecast for next year|Expected net earnings per share growth next year Sensei Biotherapeutics, Inc. (SNSE)|Net earnings per share growth forecast for next year Synthetic Biologics|Gritstone Bio - Net earnings per share change forecast for next year|Net earnings per share growth forecast for next year Kineta, Inc. (KA)|Net earnings per share growth forecast for next year NEXI (neximmune.com)|Earnings growth forecast for next year TSBX (Turnstone Biologics Corp.)|Consensus forecast of earnings per share growth for next year Vaccinex Inc. (VCNX)|HARP - Net earnings per share growth forecast for next year